Malaria, a life-threatening disease caused by parasites transmitted through the bites of infected female Anopheles mosquitoes, remains a significant public health concern in Kenya. According to the World Health Organization, in 2019, there were an estimated 229 million malaria cases and 409,000 malaria deaths worldwide, with children under 5 years of age and pregnant women being the most vulnerable groups. In Kenya, malaria is endemic, with approximately 4 million cases and 1,000 deaths reported annually. This article delves into the current malaria treatment guidelines in Kenya, focusing on the first and second lines of treatment, as well as preventive measures and special considerations.

Kenya's malaria treatment guidelines are based on the World Health Organization's (WHO) recommendations and are updated periodically to reflect the latest evidence and drug resistance trends. The primary goal of malaria treatment is to rapidly reduce the parasite burden, alleviate symptoms, and prevent complications. The choice of antimalarial medication depends on the parasite species, drug resistance patterns, and the patient's clinical condition.

First Line of Treatment
The first line of treatment for uncomplicated Plasmodium falciparum malaria, the most prevalent species in Kenya, is artemisinin-based combination therapy (ACT). ACT combines a fast-acting artemisinin derivative with a longer-acting partner drug. This approach aims to kill the parasite rapidly and prevent the development of drug resistance.

In Kenya, the recommended ACT is artemether-lumefantrine (AL), administered as six doses over three days. AL is well-tolerated, with common side effects including nausea, vomiting, and headache. It is crucial to complete the full course of treatment to ensure parasite clearance and prevent drug resistance.
Special Considerations for First Line Treatment

In cases of severe malaria, characterized by signs of organ dysfunction, impaired consciousness, or high parasite density, parenteral artesunate is the treatment of choice. This formulation is administered intramuscularly or intravenously, depending on the patient's condition and healthcare facility capabilities. The initial dose is followed by a series of doses given at 12-hour intervals until the patient can tolerate oral medication, at which point they should be switched to an ACT.
Pregnant women with malaria should receive ACT as well, with the exception of the first trimester, where ACT is contraindicated due to limited safety data. In the first trimester, quinine, a historic antimalarial, is recommended. However, ACT is preferred in the second and third trimesters due to its superior efficacy and safety profile compared to quinine.
Second Line of Treatment

In cases of treatment failure with the first-line ACT or in areas with confirmed artemisinin resistance, the second line of treatment is recommended. The current second-line treatment in Kenya is quinine plus doxycycline, administered orally for seven days. Quinine is a historic antimalarial with a long history of use, while doxycycline is a broad-spectrum antibiotic that enhances the efficacy of quinine.
Quinine plus doxycycline is generally well-tolerated, with common side effects including tinnitus, hearing loss, and gastrointestinal upset. However, it is essential to monitor patients for signs of severe adverse reactions, such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency.
Preventive Measures and Special Considerations

Malaria prevention is a critical component of controlling the disease in Kenya. The primary preventive measures include insecticide-treated mosquito nets (ITNs), indoor residual spraying (IRS), and chemoprophylaxis for high-risk groups. ITNs and IRS are recommended for all individuals living in malaria-endemic areas, while chemoprophylaxis is reserved for travelers and high-risk groups, such as pregnant women and children under 5 years of age.
In addition to these preventive measures, early diagnosis and treatment are essential for controlling malaria transmission. Kenya has implemented a policy of universal testing and treatment for all suspected malaria cases, using rapid diagnostic tests (RDTs) and microscopy. This policy aims to reduce the burden of malaria and prevent the development of drug resistance.




















In conclusion, Kenya's malaria treatment guidelines are designed to provide effective and safe treatment for all patients, with a focus on rapid parasite clearance and prevention of drug resistance. The first line of treatment, ACT, is recommended for the majority of cases, while the second line, quinine plus doxycycline, is reserved for treatment failures and areas with confirmed artemisinin resistance. Preventive measures, such as ITNs and IRS, are crucial for controlling malaria transmission and reducing the burden of the disease. Early diagnosis and treatment are essential for controlling malaria and preventing the development of drug resistance. As research continues to uncover new treatments and prevention strategies, Kenya's malaria treatment guidelines will continue to evolve to reflect the latest evidence and best practices.